[GILD] Gilead: Q3 2026 Earnings Test HIV Growth After the Q2 Stocking Boost

Gilead is a large biopharmaceutical company built mainly on HIV medicines, with products spanning HIV treatment and prevention, viral hepatitis, COVID-19 and cancer[1]. It is scheduled to hold its earnings call on 2026-10-29 to report the third quarter of 2026, ending September 30, 2026[2], and Gilead's Q3 2026 earnings arrive after a quarter that mixed strong sales with a large deal charge. In the second quarter of 2026, total revenue was $7.803 billion, up 10% year over year; product sales excluding the COVID-19 drug Veklury, which Gilead calls its base business, were $7.604 billion, HIV sales were $5.693 billion, up 12%, and royalty, contract and other revenue added $176 million[3]. The same quarter absorbed $11.183 billion of acquired in-process research and development (IPR&D) expense, leaving a non-GAAP loss of $6.75 per share[4]. On August 4 Gilead raised its full-year 2026 base-business sales guidance to $29.8 billion to $30.1 billion[5] and its non-GAAP EPS guidance excluding acquired IPR&D, financing costs and non-recurring items to $8.50 to $8.85[6]. Analyst estimates compiled by Drillr put third-quarter consensus revenue at $7.766 billion (12 analysts) and consensus EPS at $2.12 (14 analysts)[7].

Three things matter most in this report. First, can HIV treatment keep growing once the second quarter's pricing and stocking tailwinds fade? Gilead acknowledged that the end of ACA subsidies weighed on Biktarvy prescriptions and that Biktarvy's year-over-year growth came mainly from higher average realized prices on a favorable channel mix and a larger-than-expected inventory build[8]; if wholesalers draw that inventory down in the third quarter, HIV growth would step down noticeably. Second, can Yeztugo, the twice-yearly prevention injection, deliver its full-year guidance of about $1 billion[6]? It sold $397 million in the first half[9], so the second half needs about $300 million a quarter, roughly 30% above the second quarter's $232 million[3], and that depends on whether early patients keep returning at a high rate. Third, can profit and cash recover in the first quarter after the acquisitions without a large deal charge? Cash, cash equivalents and marketable debt securities stood at only $3.2 billion at the end of June[10]; whether EPS excluding acquired IPR&D lands in the roughly $2.07 to $2.25 a quarter implied by full-year guidance, and whether operating cash flow rebuilds cash after dividends, will shape buybacks and borrowing.

Company Background and Business Structure

Gilead is a biopharmaceutical company that started in antivirals and is shifting its weight toward long-acting HIV therapies and oncology. It is headquartered in Foster City, California, operates in more than 35 countries, and in late 2025 refreshed its strategic priorities to maximize the impact of long-acting HIV therapies and accelerate its pipeline build in oncology and inflammation[1]. In the first half of 2026 it closed acquisitions of Tubulis (an antibody-drug conjugate platform), Arcellx (full ownership of the multiple myeloma CAR-T anito-cel) and Ouro Medicines (a T-cell engager), and completed U.S. launches of Trodelvy in first-line metastatic triple-negative breast cancer and of Hepcludex for hepatitis delta[11].

Gilead reports a single operating segment and lists product sales by therapeutic area, with HIV dominant. In 2025 product sales were $28.915 billion: HIV $20.752 billion (about 72%, including Biktarvy at $14.334 billion and Descovy at $2.758 billion), liver disease $3.217 billion, cell therapy $1.839 billion, Trodelvy $1.397 billion and Veklury $911 million, plus $527 million of royalty and contract revenue; U.S. sales were $20.816 billion, about 72%[12]. By the second quarter of 2026 HIV's share had risen to about 75%: of $7.627 billion in product sales, HIV contributed $5.693 billion, liver disease $877 million, oncology $873 million (Trodelvy $457 million and cell therapy $417 million) and Veklury just $23 million, while U.S. sales were $5.601 billion[3].

Gilead sells almost entirely through wholesalers in the United States, so its customer concentration is high. Historically about 90% of U.S. gross product sales have gone to Cardinal Health, Cencora and McKesson and their specialty distributors, which accounted for 29%, 21% and 24% of total gross product sales in 2025[13]. Revenue is recognized at net price after Medicaid, ADAP, 340B and Medicare Part D discounts and commercial rebates, so quarterly sales move with prescriptions, payer mix and wholesaler inventory. HIV patients take medicine daily for life, Yeztugo is injected by clinics every six months, Trodelvy is infused in cancer centers, and CAR-T requires collecting a patient's cells at an authorized center, re-engineering them in a Kite plant and reinfusing them, so center count and manufacturing capacity both limit uptake.

Financial History and Current Position

Gilead's annual revenue sat around $27 billion for years, while profit swung with acquisition spending. Revenue was $27.305 billion, $27.281 billion and $27.116 billion in 2021 through 2023; in 2024 revenue reached $28.754 billion but operating income was only $1.662 billion and net income $480 million[14]. In 2025 total revenue was $29.442 billion, up about 2%, operating income recovered to $11.701 billion, net income was $8.510 billion and diluted EPS was $6.78[15]; product sales were $28.915 billion, and the base business excluding Veklury was $28.004 billion[12].

Cash generation in 2025 comfortably covered capital spending and shareholder returns. Operating cash flow was $10.019 billion, capital expenditure $563 million and free cash flow $9.456 billion; Gilead paid $4.003 billion of dividends and repurchased $1.922 billion of stock, and ended the year with total debt of $24.936 billion[15]. The company attributed the year-over-year decline in operating cash flow mainly to inventory build-up, higher income tax payments and unfavorable timing of receivable collections; it also paid the final $1.3 billion transition-tax installment on deemed repatriation of foreign earnings and repaid $1.8 billion of debt[16].

Operating performance accelerated in the first half of 2026, but reported profit was distorted by deal spending. First-quarter revenue was $6.960 billion, up 4%[17], with non-GAAP EPS of $2.03 and a 46.9% non-GAAP operating margin[18]. Second-quarter revenue was $7.803 billion (+10%) and product sales $7.627 billion (+8%)[3]; non-GAAP product gross margin was 86.9%, but $11.183 billion of acquired IPR&D turned the non-GAAP operating margin to -93.9% and produced a loss of $6.75 per share[4]. The GAAP loss was $8.45 per share[19], which also included a $1.75 billion intangible impairment after Gilead stopped a Phase 3 Trodelvy lung cancer study[20]. Gilead said the second-quarter operating margin excluding acquired IPR&D from recent acquisitions was about 49%[11].

The acquisitions nearly exhausted the cash on the balance sheet. First-half operating cash flow was $6.1 billion ($3.6 billion in the second quarter, implying about $2.5 billion in the first), but $11.3 billion of acquisition payments, $2.8 billion of debt repayment, $2.1 billion of dividends and $774 million of buybacks, net of $4.1 billion of new borrowing, cut cash, cash equivalents and marketable debt securities from $10.6 billion at the end of 2025 to $3.2 billion at the end of June[10]. Total debt was $26.246 billion on June 30, including $2.414 billion of short-term debt[21].

Operating Model

Gilead's revenue is set by three forces working together: HIV prescription volume, average realized price and wholesaler inventory. Total revenue equals product sales plus royalty, contract and other revenue, and HIV is the spine of product sales. On the treatment side Biktarvy grows through newly diagnosed patients, switches from older regimens such as Genvoya and U.S. net price[22]; on the prevention (PrEP) side sales come from daily oral Descovy and twice-yearly Yeztugo, and combined PrEP sales passed $1 billion for the first time in the second quarter[23]. Because net price depends on payer mix and inventory swings between quarters, the same prescription can bring in different revenue in different quarters: Biktarvy was held back by unfavorable inventory in the first quarter[24] and helped by favorable inventory in the second[25].

HIV sales growth converts almost one for one into profit, while acquisition charges make reported profit jump around. Non-GAAP operating income is roughly product sales times a non-GAAP product gross margin near 87%, plus other revenue, minus non-GAAP R&D ($1.429 billion in the second quarter, 18.3% of revenue), acquired IPR&D and non-GAAP SG&A ($1.521 billion in the second quarter, up 12%)[4]; the SG&A increase came mainly from HIV promotional activity[26]. Gilead books the purchase price of asset acquisitions as acquired IPR&D and keeps it inside non-GAAP profit, which is why operating income fell to $1.662 billion in 2024[14] and returned to $11.701 billion in 2025[15], and why the second-quarter 2026 non-GAAP operating margin was -93.9%[4] against about 49% excluding those charges[11].

Operating cash flow is largely insulated from acquisition charges, but the cash balance is not. Acquired IPR&D is an expense on the income statement yet an investing outflow on the cash flow statement, so operating cash flow was still $6.1 billion in the first half of 2026 even as acquisitions, debt repayment and shareholder returns pulled cash down to $3.2 billion[10]. Operating cash flow equals net income plus amortization, acquired IPR&D and other non-cash or investing-related charges, minus working-capital changes; in the second quarter Gilead paid $1.0 billion of dividends and bought back $355 million of stock[10], so the third-quarter question is whether operating cash flow covers that kind of quarterly outlay and starts lifting cash again.

Industry and Competitive Position

Gilead leads the global HIV drug market, and its core product has long patent protection. Biktarvy's primary U.S. compound patent runs to 2036[27]; its main rivals are dolutegravir-based regimens and the long-acting injection Cabenuva from ViiV Healthcare, which GSK controls. In PrEP Gilead owns both daily oral Descovy and twice-yearly Yeztugo, and says Yeztugo became the leading long-acting option for new patient starts and switches after four full quarters on the market[11]; still, 80% to 85% of the PrEP market uses daily oral pills, including a large low-priced generic segment, while the overall U.S. PrEP market grew 14% year over year[8]. ViiV's Apretude is the main long-acting injectable rival.

Oncology is a smaller business whose two parts are moving in opposite directions. Trodelvy competes in metastatic breast cancer with antibody-drug conjugates such as AstraZeneca and Daiichi Sankyo's Enhertu and Datroway; Kite's Yescarta faces both in-class CAR-T competition and out-of-class alternatives, while Tecartus is squeezed mainly by in-class competition[25], and the coming anito-cel launch will compete with Johnson & Johnson and Legend's Carvykti.

Gilead's main constraints are its heavy dependence on HIV and its direct exposure to U.S. drug pricing policy. HIV is about three-quarters of product sales, and in January 2026 Biktarvy was selected for Medicare price negotiation under the IRA, effective in 2028; Gilead anticipates a negotiated price substantially below the current Medicare price, which may also raise Medicaid rebates and lower 340B ceiling prices[28]. The available disclosures do not allow an item-by-item comparison with peers on prescriptions, net price or channel inventory, because Gilead itself does not report those figures.

Core Debates

Biktarvy's second-quarter growth leaned on higher realized prices and wholesaler stocking. Will the patients lost to the end of ACA subsidies show up in third-quarter HIV sales?

This question decides whether investors treat the second quarter as a trend or a one-off. HIV is about three-quarters of Gilead's product sales, and Biktarvy alone sold $14.334 billion in 2025[12]; in August Gilead raised its full-year HIV growth guidance from 8% to 9% to 10%[6], yet it also acknowledged that ACA subsidy changes temporarily softened the U.S. HIV treatment market and that the second-quarter outperformance came from favorable channel-mix pricing and a larger-than-expected inventory build[8]. Subtracting first-half results from full-year base-business guidance implies second-half growth slowing from about 8.8% in the first half to about 4% to 6%[5]; whether the third quarter holds that range is the first test of whether the raise is solid.

The current evidence cuts both ways. On the side of continuity, second-quarter HIV sales were $5.693 billion, up 12%, and Biktarvy was $3.772 billion, up 7%[3], and management said the HIV treatment market should return to its historical 2% to 3% annual growth[29]. On the skeptical side, Gilead itself attributed Biktarvy's growth to higher average realized price, favorable inventory dynamics and demand[25], and on the call it acknowledged that the end of ACA subsidies hurt Biktarvy volume[8]; in the first quarter Biktarvy had been held back by unfavorable inventory[24]. An alternative reading is that most of the second-quarter beat was a timing benefit from channel stocking and payer mix, that Biktarvy growth falls to the low single digits after a third-quarter drawdown, and that the full-year HIV guidance then rests mainly on PrEP.

The financial chain is short, and it lands directly on guidance. ACA subsidy changes cost some U.S. HIV patients their insurance and interrupted refills, slowing Biktarvy prescription growth; shifts in payer and channel mix lifted average realized price; wholesalers restocked in the second quarter and may draw down in the third. Together these set the year-over-year growth of HIV product sales, which in turn decides whether base-business sales stay within full-year guidance. The current baselines are second-quarter HIV sales of $5.693 billion, base-business sales of $7.604 billion and Biktarvy sales of $3.772 billion[3]. What remains unresolved is that Gilead does not disclose prescriptions, net price or channel inventory amounts, so outsiders can only separate price, inventory and demand through growth rates and management's wording.

The third-quarter report should answer four things: whether HIV sales grow at least 7% year over year; how fast Biktarvy grows and what Gilead says about inventory and average realized price; whether base-business sales grow at least 4% and the $29.8 billion to $30.1 billion full-year guidance holds[5]; and how Gilead describes the treatment market's recovery after ACA coverage losses. If Biktarvy grows less than 4% and Gilead blames an inventory drawdown, or if Gilead cuts its HIV or base-business guidance, the second quarter was mainly a one-off and the current reading of the raise would need revising.

A year after launch, can Yeztugo sell more than $260 million in the third quarter without Descovy shrinking to pay for it?

PrEP is the fastest-growing part of Gilead's HIV business, and its direction shows whether Gilead is expanding the market or shifting patients between its own products. Combined PrEP sales passed $1 billion for the first time in the second quarter[23]; with $397 million of Yeztugo sales in the first half[9], full-year Yeztugo guidance of about $1 billion[6] requires about $603 million in the second half, or roughly $300 million a quarter, about 30% above the second quarter. Meanwhile Descovy's strong growth is mostly price: its 48% year-over-year increase in the second quarter was driven first by higher average realized price and only then by demand[25].

The evidence for uptake is that Yeztugo sold $232 million in the second quarter, up 40% sequentially, with a 12-month persistence rate that Gilead put at 70%[23], and that it has become the leading long-acting choice for new PrEP starts and switches[11], in a U.S. PrEP market that grew 14%[8]. The evidence against is that an analyst on the call pointed to a gap between IQVIA prescription data and Gilead's reported sales, which Gilead declined to discuss[8], and that Leerink Partners analyst Daina Graybosch argued early adopters are highly persistent patients who sought out Yeztugo, flagging a "meaningful risk of return rate degradation"[30]. An alternative reading is that second-quarter growth included a concentrated wave of first patients returning for their second injection, so sequential gains shrink in the third quarter as new-patient growth slows.

Yeztugo revenue is the number of people starting prevention or switching from daily pills, multiplied by the second-dose return rate, which sets injection volume; Descovy revenue is PrEP users times average realized price. Together they make up PrEP sales, which feed HIV product sales. The current baselines are second-quarter Yeztugo sales of $232 million and Descovy sales of $967 million[3], of which $801 million, about 80% of Descovy, was for PrEP[23]; in the first quarter the two products sold $166 million and $807 million[17]. What remains unresolved is that Gilead does not disclose PrEP patient counts or the split between new and switching patients, so how much of Yeztugo's growth comes from Descovy users versus new users rests on management's commentary.

The third-quarter report should answer four things: whether Yeztugo sells at least $260 million and full-year guidance of about $1 billion holds; whether Descovy stays above $900 million and what Gilead says about its price and patient numbers; whether Gilead updates persistence and the new-versus-switch mix; and whether the FDA review of once-weekly oral lenacapavir for PrEP stays on track for its February 2027 decision date[11]. If Yeztugo comes in below $260 million, or Descovy falls more than 7% sequentially while Yeztugo grows, uptake is running behind the guidance pace or is mostly a switch between Gilead's own products.

Can Trodelvy's new first-line triple-negative breast cancer approval offset the continuing slide in Kite's cell therapies?

Oncology is Gilead's main route away from HIV dependence, yet growth in its existing oncology business has nearly stalled. Oncology sales grew only 3% in the second quarter: Trodelvy rose 26% while cell therapy fell 14%[3]. Gilead has just booked about $10.1 billion of acquired IPR&D for two oncology assets, Arcellx ($7.0 billion) and Tubulis ($3.1 billion)[26], and took a $1.75 billion impairment after stopping a Phase 3 Trodelvy lung cancer study[20]. Whether oncology returns to mid-single-digit growth in the third quarter decides whether the existing business can support this diversification spending before anito-cel launches.

The supporting evidence is that Trodelvy sold $457 million in the second quarter, up 13% sequentially, which Gilead says puts it near a $1.8 billion annual run rate[23]; it added the first-line triple-negative breast cancer indication in the first half, and anito-cel launch preparation is complete ahead of a December 23, 2026 FDA decision date[11]. The opposing evidence is that cell therapy keeps shrinking, down 12% in the first quarter[24] and 14% in the second[25], with Gilead maintaining guidance for a mid-teens decline for the year[6], and that the EVOKE-03 study of Trodelvy in non-small cell lung cancer has been discontinued[20]. An alternative reading is that part of Trodelvy's first-half strength came from favorable first-quarter inventory[24] and initial use in the new indication, so once its growth cools in the third quarter, total oncology growth approaches zero.

The financial transmission runs along two opposing lines. Trodelvy's first-line triple-negative breast cancer approval adds treatable patients and lifts Trodelvy sales; Yescarta and Tecartus face in-class and out-of-class competition, fewer patients are infused and cell therapy sales fall; the two net out to oncology product sales. If anito-cel is approved on schedule, it adds new cell therapy revenue only from 2027. The current baselines are second-quarter oncology sales of $873 million, Trodelvy at $457 million and cell therapy at $417 million (Yescarta $346 million, Tecartus $70 million)[3]; first-half oncology sales were $1.683 billion, up 5%[9]. What remains unresolved is that Gilead has not quantified either the durable scale of Trodelvy's new indication or when Kite's decline will bottom.

The third-quarter report should answer four things: whether oncology sales grow at least 5% year over year; whether Trodelvy keeps growing sequentially to at least $470 million; whether cell therapy holds above $350 million; and whether the anito-cel review stays on its December 23, 2026 timetable. If oncology sales turn to a year-over-year decline, or the anito-cel review is delayed, the existing oncology business cannot carry the diversification story and the return on the acquired assets arrives later than Gilead describes.

After $11.2 billion of acquired R&D, can Gilead hold its margins while HIV promotion costs climb, and start rebuilding cash?

The third quarter is the first clean quarter after the acquisitions, and it will shape how investors judge the deals and capital returns. In the second quarter Gilead expensed the Arcellx, Tubulis and Ouro acquisitions at once, producing a non-GAAP loss of $6.75 per share[19], and cash and marketable securities fell from $10.6 billion at the start of the year to $3.2 billion[10]. Full-year guidance of $8.50 to $8.85 in EPS excluding IPR&D[6], minus about $4.36 earned in the first half, implies roughly $2.07 to $2.25 a quarter in the second half; whether the third quarter lands in that range and whether operating cash flow covers dividends and buybacks are the most direct tests of post-deal earnings and cash strength.

The supporting evidence is that the second-quarter operating margin excluding acquired IPR&D was about 49%[11], non-GAAP product gross margin held flat at 86.9% and non-GAAP R&D fell 1% year over year[4]; Gilead raised the low end of its EPS guidance excluding IPR&D and said it does not plan further large acquisitions in 2026[6]. The opposing evidence is that non-GAAP SG&A has grown 12% year over year for two straight quarters[18], base-business guidance implies second-half growth slowing to about 4% to 6%, and at the end of June total debt was about $26.2 billion[21] against only $3.2 billion of cash[10]. An alternative reading is that slower second-half revenue combined with promotional spending pushes EPS excluding IPR&D to the low end of the range, cash rebuilds more slowly than hoped and buybacks stay limited.

Profit transmits as follows: product sales, mostly HIV, times a non-GAAP product gross margin near 87%, minus non-GAAP R&D, non-GAAP SG&A driven largely by HIV promotion and acquired IPR&D, gives non-GAAP operating income and EPS; operating income after taxes and working-capital changes gives operating cash flow, and after dividends and buybacks that sets the cash balance and debt. The current baselines are second-quarter non-GAAP EPS excluding acquired IPR&D of about $2.33 (derived by adding the $9.08 per-share IPR&D and tax impact back to the $6.75 non-GAAP loss)[19], non-GAAP SG&A of $1.521 billion[4], operating cash flow of $3.6 billion and period-end cash and marketable securities of $3.2 billion[10]. What remains unresolved is that the $2.33 figure is an approximation; Gilead does not separately report quarterly EPS excluding IPR&D.

The third-quarter report should answer four things: whether non-GAAP EPS excluding acquired IPR&D is at least $2.07; whether non-GAAP SG&A grows no more than 15%; whether operating cash flow is at least $2.5 billion and period-end cash rises; and whether Gilead keeps its $8.50 to $8.85 EPS guidance excluding IPR&D and announces any new deal. If EPS excluding IPR&D falls below $2.07, or operating cash flow is below $2.5 billion while cash keeps falling, post-deal profit and cash are recovering more slowly than the guidance implies.

Risks and Falsifiers

U.S. drug pricing policy is Gilead's largest medium-term risk. Biktarvy has been selected for Medicare price negotiation under the IRA, effective in 2028, and Gilead anticipates a negotiated price substantially below the current one, with possible knock-on increases in rebates to Medicaid and potentially other segments and lower 340B ceiling prices[31]; the Medicare Part D redesign already lowered Biktarvy's average realized price in 2025[22]. The exposed lines are Biktarvy's $14.334 billion of 2025 sales and $16.904 billion of U.S. HIV sales[12]; the third quarter is not directly affected, but any early concession on net price would hit sales immediately. If the third-quarter report still cites higher average realized price as a driver of HIV growth and Gilead flags no new U.S. pricing adjustment, the risk has not materialized in the near term.

Patent and exclusivity risk is limited in the short run but caps the long-term growth of products other than Biktarvy. Primary EU compound patents on Descovy, Odefsey and Vemlidy expire in 2027, the U.S. patents on Tecartus in 2027 and on Trodelvy in 2028, while Biktarvy's U.S. patent runs to 2036[27]. The exposed lines are Trodelvy's $307 million of U.S. sales in the second quarter and about $94 million of combined European sales of Descovy, Odefsey and Vemlidy[3]. If Gilead discloses no adverse patent litigation outcome or early generic entry around the third-quarter report, the risk remains a distant one.

An inventory and price give-back is the most immediate third-quarter risk. In the second quarter Biktarvy offset slower prescriptions with favorable channel-mix pricing and a larger-than-expected inventory build[8], and that could reverse in the third. The exposed line is about $3.772 billion of quarterly Biktarvy sales[3]: each percentage point of lost growth removes about $35 million of quarterly sales, nearly all of which falls to profit at a non-GAAP product gross margin near 87%[4]. If Biktarvy grows at least 6% year over year in the third quarter and Gilead flags no inventory drawdown, the second-quarter gain was not purely a matter of timing.

Slower Yeztugo uptake or falling persistence would directly weaken delivery of the full-year HIV guidance. After the early highly persistent adopters, new patients come increasingly from groups with historically low PrEP use, return rates could fall, and third-party prescription data show growth slowing[8]. The exposed line is the roughly $603 million of the about $1 billion full-year guidance still to be delivered in the second half[9]; every $50 million of quarterly shortfall equals about 0.9 percentage points of quarterly HIV sales. If third-quarter Yeztugo sales are at least $290 million and Gilead reports persistence of at least 70%, uptake is on the guidance pace.

The risk of failed oncology diversification is that cell therapy declines faster than Trodelvy grows, while the Arcellx and Tubulis acquisitions produce no revenue until after 2027. The exposed lines are about $873 million of quarterly oncology sales[3], about $10.1 billion of second-quarter acquired IPR&D spent on oncology assets (Arcellx $7.0 billion and Tubulis $3.1 billion)[26] and the $1.75 billion Trodelvy lung cancer intangible impairment[20]. If third-quarter oncology sales grow at least 5% year over year and anito-cel is approved on schedule, the risk has not materialized for now.

Post-deal balance sheet pressure limits Gilead's room to maneuver. Cash has fallen to $3.2 billion against total debt of about $26.2 billion, while quarterly dividends run about $1.0 billion[10], so a new deal or weaker operating cash flow would force more borrowing or smaller buybacks[21]. The exposed items are about $2 billion of notes due in 2027 ($1.25 billion in March and $750 million in October) and annual dividends of about $4 billion ($4.003 billion in 2025)[15]. If third-quarter operating cash flow is at least $3.0 billion, period-end cash recovers above $4.5 billion and total debt does not rise, the balance sheet is being repaired.

What to Watch Next

• HIV treatment pricing, inventory and ACA coverage losses: watch HIV, Biktarvy and base-business sales against second-quarter levels of $5.693 billion (+12%), $3.772 billion (+7%) and $7.604 billion, plus Gilead's explanation of inventory and realized price and whether the $29.8 billion to $30.1 billion guidance holds. HIV growth of at least 7% and base-business growth of at least 4% confirm; Biktarvy growth below 4% blamed on destocking, or a guidance cut, refutes.
• Yeztugo uptake and Descovy switching: watch Yeztugo sales, Descovy sales and persistence against $232 million, $967 million and 70%, plus the about $1 billion guidance, the new-versus-switch mix and the weekly oral PrEP review. Yeztugo of at least $260 million with Descovy above $900 million confirms; Yeztugo below $260 million, or Descovy down more than 7% sequentially while Yeztugo grows, refutes.
• Trodelvy versus the cell therapy slide: watch oncology, Trodelvy, cell therapy and the anito-cel review against $873 million (+3%), $457 million and $417 million, including whether the December 23 decision stays on schedule. Oncology growth of at least 5% confirms; an oncology decline or an anito-cel delay refutes.
• Post-deal earnings and cash: watch EPS excluding acquired IPR&D, non-GAAP SG&A, operating cash flow and period-end cash against about $2.33, $1.521 billion, $3.6 billion and $3.2 billion, plus whether the $8.50 to $8.85 guidance holds and any new deal. EPS of at least $2.07 and operating cash flow of at least $2.5 billion with rising cash confirm; EPS below $2.07, or operating cash flow below $2.5 billion with falling cash, refutes.

Conclusion

Gilead's business is driven by HIV, and its current financial condition combines strong operations with a tight balance sheet. HIV contributed $5.693 billion in the second quarter, about three-quarters of product sales[3], and with a non-GAAP product gross margin near 87% the operating margin excluding acquired IPR&D was about 49%[11]; but $11.183 billion of acquisition charges[4] pushed cash and marketable securities down to $3.2 billion[10] against total debt of about $26.2 billion[21]. The central unresolved relationship is how much of the second quarter's HIV growth reflects durable demand and Yeztugo uptake, and how much reflects timing benefits from price and inventory; that decides how fully the full-year guidance is delivered and whether second-half operating cash flow can rebuild cash.

Outside interpretation since the second-quarter report has centered on whether PrEP uptake can last. Leerink Partners analyst Daina Graybosch saw "several uncertain Yeztugo signals" in Gilead's presentation: Gilead itself says 80% to 85% of the PrEP market prefers oral medicines, the path to double-digit growth likely runs through communities with historically low PrEP use, and today's early adopters are highly persistent patients who actively sought out Yeztugo, so return rates face a meaningful risk of degrading as prescription trends slow, as reported by BioPharma Dive[30]. That view conflicts directly with the 70% persistence and about $1 billion full-year guidance Gilead cites[6] and maps onto the second core debate; it questions not the $232 million of second-quarter sales but the persistence and new-patient sources behind the roughly $600 million needed in the second half. Since the second-quarter report this is the only independent assessment with a clear analytical position that could be identified, with the rest mostly restating results, so it represents one firm's judgment rather than a market view, and the HIV treatment, oncology and capital allocation debates still lack independent outside interpretation.

The combination that would materially strengthen the current understanding is Biktarvy growing at least 6% year over year with no inventory drawdown flagged, Yeztugo selling at least $260 million in the third quarter with Gilead confirming persistence of at least 70%, oncology growth returning above 5%, and EPS excluding acquired IPR&D of at least $2.07 alongside operating cash flow of at least $2.5 billion and rising period-end cash. Conversely, if Biktarvy growth drops below 4% on a destocking, Yeztugo falls short of $260 million, oncology turns to a year-over-year decline and cash keeps sliding, the second quarter's strength was mainly timing, and post-deal Gilead depends more on HIV pricing and channel rhythm than its guidance suggests.

Sources

[1] GILD 10-K filed 2026-02-24 · management overview and strategic priorities · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[2] Drillr earnings calendar (updated 2026-09-28) · GILD 2026-10-29 call · 2026-09-28 · Drillr earnings calendar

[3] GILD 10-Q filed 2026-08-06 · Q2 2026 revenues by product · 2026-08-06 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-Q

[4] GILD 8-K filed 2026-08-04 · Q2 2026 non-GAAP financial information · 2026-08-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[5] GILD 8-K filed 2026-08-04 · August 2026 full-year guidance · 2026-08-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[6] GILD Q2 2026 earnings call 2026-08-04 · 2026 guidance detail · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[7] Drillr analyst_financial_estimates (updated 2026-09-28) · GILD quarter ending 2026-09-30 · 2026-09-28 · Drillr analyst_financial_estimates · https://gateway.drillr.ai/mcp/private

[8] GILD Q2 2026 earnings call 2026-08-04 · Q&A on Biktarvy and Yeztugo · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[9] GILD 10-Q filed 2026-08-06 · H1 2026 revenues by product · 2026-08-06 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-Q

[10] GILD 8-K filed 2026-08-04 · cash, operating cash flow and capital return · 2026-08-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[11] GILD Q2 2026 earnings call 2026-08-04 · launches, pipeline and margins · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[12] GILD 10-K filed 2026-02-24 · FY2025 product sales by franchise · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[13] GILD 10-K filed 2026-02-24 · commercialization and wholesaler concentration · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[14] GILD 10-K filed 2025-02-28 · FY2021-FY2024 revenue and operating income · 2025-02-28 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-K

[15] GILD 10-K filed 2026-02-24 · FY2025 income, cash flow and balance sheet · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[16] GILD 10-K filed 2026-02-24 · liquidity and capital return 2025 · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[17] GILD 10-Q filed 2026-05-07 · Q1 2026 revenues by product · 2026-05-07 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-Q

[18] GILD 8-K filed 2026-05-07 · Q1 2026 non-GAAP financial information · 2026-05-07 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[19] GILD 8-K filed 2026-08-04 · Q2 2026 results headline · 2026-08-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[20] GILD 10-Q filed 2026-08-06 · acquired IPR&D and Trodelvy NSCLC impairment · 2026-08-06 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-Q

[21] GILD 10-Q filed 2026-08-06 · June 30 2026 debt and cash · 2026-08-06 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-Q

[22] GILD 10-K filed 2026-02-24 · FY2025 franchise sales drivers · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[23] GILD Q2 2026 earnings call 2026-08-04 · segment performance · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[24] GILD 8-K filed 2026-05-07 · Q1 2026 product sales commentary · 2026-05-07 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[25] GILD 8-K filed 2026-08-04 · Q2 2026 product sales commentary · 2026-08-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[26] GILD 8-K filed 2026-08-04 · Q2 2026 margin, expenses and acquired IPR&D · 2026-08-04 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=8-K

[27] GILD 10-K filed 2026-02-24 · U.S. and EU patent expiration · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[28] GILD 10-K filed 2026-02-24 · IRA Medicare negotiation of Biktarvy · 2026-02-24 · 10-K · https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/

[29] GILD Q2 2026 earnings call 2026-08-04 · stated risks · 2026-08-04 · earnings-call · https://gateway.drillr.ai/mcp/private

[30] BioPharma Dive 2026-08-05 · Earnings roundup: Gilead's 'uncertain' future · 2026-08-05 · BioPharma Dive (reporting Leerink Partners) · https://www.biopharmadive.com/news/pfizer-merck-gilead-earnings-2q-2026-analysis/827029/

[31] GILD 10-Q filed 2026-08-06 · IRA and pricing pressure · 2026-08-06 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000882095&type=10-Q